Director Arthur Levin of Avidity Biosciences (RNA) logs automatic tax sell of 1,758 shares

Rhea-AI Filing Summary

Avidity Biosciences director Arthur A. Levin reported an automatic sale of common stock tied to RSU vesting. On January 21, 2026, 1,758 shares of Avidity Biosciences common stock were sold at $72.45 per share in a transaction coded "S." According to the footnote, this was a mandated "sell-to-cover" sale to satisfy tax withholding obligations from restricted stock units that vested on January 20, 2026, under the company’s equity incentive plans, and it was not a discretionary trade. After this sale, Levin directly held 16,562 common shares, and additional common shares were held indirectly through a family trust and a charitable remainder trust. The filing notes that instructions for these automatic sell-to-cover transactions were established under Rule 10b5-1.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LEVIN ARTHUR A

(Last) (First) (Middle)

C/O AVIDITY BIOSCIENCES, INC.

3020 CALLAN ROAD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Avidity Biosciences, Inc. [ RNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/21/2026		S		1,758(1)	D	$72.45	16,562	D
Common Stock								131,372	I	By family trust
Common Stock								22,500	I	By charitable remainder trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2026 and the sale of the resulting shares of common stock on January 21, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1.

Remarks:

	/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Avidity Biosciences (RNA) disclose for Arthur A. Levin?

The filing shows that director Arthur A. Levin reported a sale of 1,758 shares of Avidity Biosciences common stock on January 21, 2026, at $72.45 per share.

Was Arthur A. Levins sale of Avidity Biosciences (RNA) shares a discretionary trade?

No. The footnote explains the sale was a mandated "sell-to-cover" transaction to cover tax withholding obligations from RSUs that vested on January 20, 2026, and does not represent a discretionary trade by Levin.

How many Avidity Biosciences (RNA) shares does Arthur A. Levin hold after the reported transaction?

Following the sell-to-cover transaction, Levin directly owned 16,562 common shares. He also had indirect holdings of 131,372 common shares through a family trust and 22,500 common shares through a charitable remainder trust.

What is a "sell-to-cover" transaction in the context of Avidity Biosciences (RNA)?

In this context, a sell-to-cover transaction means that shares received from RSU vesting were automatically sold to generate cash to pay tax withholding obligations, as required by the companys equity incentive plans.

Did Arthur A. Levin use a Rule 10b5-1 plan for this Avidity Biosciences (RNA) transaction?

Yes. The footnote states that Levin executed an instruction letter for the automatic sale of sell-to-cover shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1.

What roles does Arthur A. Levin have at Avidity Biosciences (RNA)?

The filing identifies Arthur A. Levin as a director of Avidity Biosciences, Inc. He is not listed as an officer or 10% owner in this report.